Virginia Retirement Systems ET AL bought a new stake in shares of Cambrex Corp. (NYSE:CBM) during the second quarter, Holdings Channel reports. The fund bought 21,300 shares of the company’s stock, valued at approximately $1,102,000. Virginia Retirement Systems ET AL owned about 0.07% of Cambrex Corp. at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in CBM. Blair William & Co. IL boosted its stake in shares of Cambrex Corp. by 0.3% in the second quarter. Blair William & Co. IL now owns 17,301 shares of the company’s stock worth $895,000 after buying an additional 60 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Cambrex Corp. by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 14,200 shares of the company’s stock worth $735,000 after buying an additional 100 shares in the last quarter. PineBridge Investments L.P. boosted its stake in shares of Cambrex Corp. by 4.4% in the second quarter. PineBridge Investments L.P. now owns 4,056 shares of the company’s stock worth $210,000 after buying an additional 171 shares in the last quarter. Insight Capital Research & Management Inc. boosted its stake in shares of Cambrex Corp. by 0.3% in the first quarter. Insight Capital Research & Management Inc. now owns 70,136 shares of the company’s stock worth $3,086,000 after buying an additional 180 shares in the last quarter. Finally, Aperio Group LLC boosted its stake in shares of Cambrex Corp. by 3.0% in the first quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock worth $333,000 after buying an additional 221 shares in the last quarter. Hedge funds and other institutional investors own 99.46% of the company’s stock.
Cambrex Corp. (NYSE:CBM) opened at 44.46 on Friday. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 22.48 and a beta of 1.45. Cambrex Corp. has a 12-month low of $29.50 and a 12-month high of $59.41. The company’s 50 day moving average price is $45.06 and its 200-day moving average price is $47.67.
Cambrex Corp. (NYSE:CBM) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.09. The business earned $118.22 million during the quarter, compared to analyst estimates of $114.85 million. Cambrex Corp. had a return on equity of 24.86% and a net margin of 13.97%. Cambrex Corp.’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 EPS. On average, equities analysts anticipate that Cambrex Corp. will post $2.56 earnings per share for the current fiscal year.
Separately, Zacks Investment Research upgraded Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $55.00 price objective on the stock in a research note on Wednesday, August 3rd.
In other Cambrex Corp. news, Director William B. Korb sold 3,420 shares of the company’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the transaction, the director now owns 23,982 shares of the company’s stock, valued at approximately $1,319,010. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.63% of the company’s stock.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.